B-cell lymphoma-2 promotes malignant progression in glioma

Clinical Neurosurgery

Volumn 58, Issue , 2011, Pages 149-154

  Doucette, Tiffany A ^a   Rao, Ganesh ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

NESTIN; PROTEIN BCL 2; PLATELET DERIVED GROWTH FACTOR B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; APOPTOTIC ASSAY; ASSAY; CANCER GROWTH; CONFERENCE PAPER; CONTROLLED STUDY; GENE OVEREXPRESSION; GENETIC TRANSFECTION; GLIOMA; HISTOPATHOLOGY; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MITOSIS INDEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOMATIC CELL; WESTERN BLOTTING; ANIMAL; ARTICLE; BRAIN TUMOR; DISEASE MODEL; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROTO ONCOGENE; TRANSGENIC MOUSE;

ANIMALS; BRAIN NEOPLASMS; DISEASE MODELS, ANIMAL; GENES, BCL-2; GLIOMA; MICE; MICE, TRANSGENIC; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-SIS;

EID: 80155124144     PISSN: 00694827     EISSN: 0148396X     Source Type: Journal    
DOI: 10.1227/NEU.0b013e3182269d15     Document Type: Conference Paper

References (49)

1. Cairncross G, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol. 2006;24(18):2707-2714. (Pubitemid 46630566)
2. Jaeckle KA, Ballman KV, Rao RD, Jenkins RB, Buckner JC. Current strategies in treatment of oligodendroglioma: evolution of molecular signatures of response. J Clin Oncol. 2006;24(8):1246-1252. (Pubitemid 46622027)
3. van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol. 2006;24(18):2715-2722. (Pubitemid 46630567)
4. Di Rocco F, Carroll RS, Zhang J, Black PM. Platelet-derived growth factor and its receptor expression in human oligodendrogliomas. Neurosurgery. 1998;42(2):341-346. (Pubitemid 28076794)
5. Nister M, Libermann TA, Betsholtz C, et al. Expression of messenger RNAs for platelet-derived growth factor and transforming growth factor-alpha and their receptors in human malignant glioma cell lines. Cancer Res. 1988;48(14):3910-3198.
6. Robinson S, Cohen M, Prayson R, Ransohoff RM, Tabrizi N, Miller RH. Constitutive expression of growth-related oncogene and its receptor in oligodendrogliomas. Neurosurgery. 2001;48(4):864-873.
7. Shih AH, Holland EC. Platelet-derived growth factor (PDGF) and glial tumorigenesis. Cancer Lett. 2006;232(2):139-147. (Pubitemid 43170963)
8. Shih AH, Dai C, Hu X, Rosenblum MK, Koutcher JA, Holland EC. Dose-dependent effects of platelet-derived growth factor-B on glial tumorigenesis. Cancer Res. 2004;64:4783-4789. (Pubitemid 38924521)
9. Appolloni I, Calzolari F, Tutucci E, et al. PDGF-B induces a homogeneous class of oligodendrogliomas from embryonic neural progenitors. Int J Cancer. 2009;124(10):2251-2259.
10. Dai C, Celestino JC, Okada Y, Louis DN, Fuller GN, Holland EC. PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev. 2001;15(15):1913-1925. (Pubitemid 32738621)
11. Uhrbom L, Hesselager G, Nister M, Westermark B. Induction of brain tumors in mice using a recombinant platelet-derived growth factor B-chain retrovirus. Cancer Res. 1998;58(23):5275-5279. (Pubitemid 28551098)
12. Dunlap SM, Celestino J, Wang H, et al. Insulin-like growth factor binding protein 2 promotes glioma development and progression. Proc Natl Acad Sci U S A. 2007;104(28):11736-11741. (Pubitemid 47175082)
13. Huse JT, Brennan C, Hambardzumyan D, et al. The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes Dev. 2009;23(11):1327-1337.
14. Tchougounova E, Kastemar M, Brasater D, Holland EC, Westermark B, Uhrbom L. Loss of Arf causes tumor progression of PDGFB-induced oligodendroglioma. Oncogene. 2007;26(43):6289-6296. (Pubitemid 47462106)
15. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1): 57-70. (Pubitemid 30046295)
16. Yip KW, Reed JC. Bcl-2 family proteins and cancer. Oncogene. 2008; 27(50):6398-6406.
17. Andrews GA, Xi S, Pomerantz RG, et al. Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl-2 expression and increased susceptibility to cisplatin-induced apoptosis. Head Neck. 2008; 26(10):870-877.
18. Ikegaki N, Katsumata M, Minna J, Tsujimoto Y. Expression of bcl-2 in small cell lung carcinoma cells. Cancer Res. 1994;54(1):6-8. (Pubitemid 24042076)
19. Monni O, Joensuu H, Franssila K, Klefstrom J, Alitalo K, Knuutila S. BCL2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphoma. Blood. 1997;90(3):1168-1174. (Pubitemid 27314153)
20. Sharma H, Sen S, Mathur M, Bahadur S, Singh N. Combined evaluation of expression of telomerase, survivin, and anti-apoptotic Bcl-2 family members in relation to loss of differentiation and apoptosis in human head and neck cancers. Head Neck. 2004;26(8):733-740. (Pubitemid 39014639)
21. Bruggers CS, Fults D, Perkins SL, Coffin CM, Carroll WL. Coexpression of genes involved in apoptosis in central nervous system neoplasms. J Pediatr Hematol Oncol. 1999;21(1):19-25. (Pubitemid 29131989)
22. Strik H, Deininger M, Streffer J, et al. BCL-2 family protein expression in initial and recurrent glioblastomas: modulation by radiochemotherapy. J Neurol Neurosurg Psychiatry. 1999;67(6):763-768.
23. Stegh AH, Chin L, Louis DN, DePinho RA. What drives intense apoptosis resistance and propensity for necrosis in glioblastoma? A role for Bcl2L12 as a multifunctional cell death regulator. Cell Cycle. 2008; 7(18):2833-2839.
24. McDonald FE, Ironside JW, Gregor A, et al. The prognostic influence of bcl-2 in malignant glioma. Br J Cancer. 2002;86(12):1899-1904.
25. Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE, Fuller GN. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet. 2000;25(1):55-57. (Pubitemid 30257036)
26. Holland EC, Li Y, Celestino J, et al. Astrocytes give rise to oligodendrogliomas and astrocytomas after gene transfer of polyoma virus middle T antigen in vivo. Am J Pathol. 2000;157(3):1031-1037. (Pubitemid 32109394)
27. Rao G, Pedone CA, Coffin CM, Holland EC, Fults DW. c-Myc enhances sonic hedgehog-induced medulloblastoma formation from nestin-expressing neural progenitors in mice. Neoplasia. 2003;5:198-204. (Pubitemid 36754051)
28. Rao G, Pedone CA, Del Valle L, Reiss K, Holland EC, Fults DW. Sonic hedgehog and insulin-like growth factor signaling synergize to induce medulloblastoma formation from nestin-expressing neural progenitors in mice. Oncogene. 2004;23(36):6156-6162. (Pubitemid 39178868)
29. McCall TD, Pedone CA, Fults DW. Apoptosis suppression by somatic cell transfer of Bcl-2 promotes Sonic hedgehog-dependent medulloblastoma formation in mice. Cancer Res. 2007;67(11):5179-5185. (Pubitemid 46997255)
30. Holland EC, Varmus HE. Basic fibroblast growth factor induces cell migration and proliferation after glia-specific gene transfer in mice. Proc Natl Acad Sci U S A. 1988;95(3):1218-1223.
31. Green DR, Evan GI. A matter of life and death. Cancer Cell 2002;1(1):19-30. (Pubitemid 41039172)
32. Newcomb EW, Bhalla SK, Parrish CL, Hayes RL, Cohen H, Miller DC. Bcl-2 protein expression in astrocytomas in relation to patient survival and p53 gene status. Acta Neuropathol. 1997;94(4):369-375. (Pubitemid 27450118)
33. Newcomb EW, Cohen H, Lee SR, et al. Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes. Brain Pathol. 1998;8(4):655-667. (Pubitemid 28460924)
34. Deininger MH, Weller M, Streffer J, Meyermann R. Antiapoptotic Bcl-2 family protein expression increases with progression of oligodendroglioma. Cancer. 1999;86(9):1832-1839. (Pubitemid 29513054)
35. Martin S, Toquet C, Oliver L, et al. Expression of bcl-2, bax and bcl-xl in human gliomas: a re-appraisal. J Neurooncol. 2001;52(2):129-139. (Pubitemid 32691175)
36. Rieger L, WellerM, Bornemann A, SchabetM, Dichgans J,Meyermann R. BCL-2 family protein expression in human malignant glioma: a clinical-pathological correlative study. J Neurol Sci. 1998;155(1):68-75. (Pubitemid 28141061)
37. Hara A, Hirose Y, Yoshimi N, Tanaka T, Mori H. Expression of Bax and bcl-2 proteins, regulators of programmed cell death, in human brain tumors. Neurol Res. 1997;19(6):623-628. (Pubitemid 28006646)
38. Krajewski S, Krajewska M, Ehrmann J, et al. Immunohistochemical analysis of Bcl-2, Bcl-X, Mcl-1, and Bax in tumors of central and peripheral nervous system origin. Am J Pathol. 1997;150(3):805-814. (Pubitemid 27106152)
39. Weller M, Malipiero U, Aguzzi A, Reed JC, Fontana A. Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest. 1995;95(6):2633-2643.
40. Wick W, Wagner S, Kerkau S, Dichgans J, Tonn JC, Weller M. BCL-2 promotes migration and invasiveness of human glioma cells. FEBS Lett. 1998;440(3):419-424. (Pubitemid 29052326)
41. Reed JC. Bcl-2-family proteins and hematologic malignancies: history and future prospects. Blood. 2008;111(7):3322-3330.
42. Arai M, Sasaki A, Saito N, Nakazato Y. Immunohistochemical analysis of cleaved caspase-3 detects high level of apoptosis frequently in diffuse large B-cell lymphomas of the central nervous system. Pathol Int. 2005; 55(3):122-129. (Pubitemid 40477223)
43. Stegh AH, Kesari S, Mahoney JE, et al. Bcl2L12-mediated inhibition of effector caspase-3 and caspase-7 via distinct mechanisms in glioblastoma. Proc Natl Acad Sci U S A. 2008;105(31):10703-10708.
44. Stegh AH, Kim H, Bachoo RM, et al. Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma. Genes Dev. 2007; 21(1):98-111. (Pubitemid 46089711)
45. Moyano JV, Evans JR, Chen F, et al. AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest. 2006;116(1):261-270. (Pubitemid 43121811)
46. Jiang Z, Zheng X, Rich KM. Down-regulation of Bcl-2 and Bcl-xL expression with bispecific antisense treatment in glioblastoma cell lines induce cell death. J Neurochem. 2003;84(2):273-281. (Pubitemid 36182269)
47. Julien T, Frankel B, Longo S, et al. Antisense-mediated inhibition of the bcl-2 gene induces apoptosis in human malignant glioma. Surg Neurol. 2000;53(4):360-368.
48. Hetschko H, Voss V, Horn S, Seifert V, Prehn JH, Kogel D. Pharmacological inhibition of Bcl-2 family members reactivates TRAIL-induced apoptosis in malignant glioma. J Neurooncol. 2008; 86(3):265-272.
49. Tagscherer KE, Fassl A, Campos B, et al. Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. Oncogene. 2008;27(52):6646-6656.